News
Apr 11, 2022
Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting
New clinical biomarker data from Phase 1 monotherapy trial of RBN-2397 provide evidence for immune cell infiltration in patient tumors upon treatment, providing strong rationale …
Learn MoreMar 29, 2022
Ribon Therapeutics Announces Initiation of Phase 1b/2 Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung
–RBN-2397 is a novel first-in-class oral PARP7 inhibitor that increases immune cell infiltration into tumors and is expected to improve outcomes of patients treated with …
Learn MoreMar 22, 2022
Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis
– Ribon’s portfolio now includes two first-in-class clinical programs, RBN-2397 and RBN-3143, targeting broad indications in oncology and inflammatory diseases Cambridge, MA – March 22, …
Learn MoreFeb 17, 2022
Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth
-Prakash Raman, Ph.D., appointed as President and Chief Executive Officer- -Victoria Richon, Ph.D., to remain as an R&D Advisor to the Board of Directors and …
Learn MoreSep 27, 2021
Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech
Cambridge, MA – September 27, 2021 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been …
Learn MoreSep 01, 2021
Ribon Therapeutics Announces Key Management Promotions
Heike Keilhack, Ph.D., Promoted to Chief Scientific Officer Kevin Kuntz, Ph.D., Promoted to Chief Drug Development Officer Cambridge, MA – September 1, 2021 – Ribon …
Learn MoreJul 22, 2021
Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397
Small molecule inhibitor of PARP7 restores Type I interferon signaling in tumor cells Data validate therapeutic strategy of targeting PARP7, a key vulnerability in cancer …
Learn MoreJul 14, 2021
Ribon Therapeutics Secures $65 Million Financing
Proceeds Support Advancement of Lead Product Candidates RBN-2397 and RBN-3143 Through Key Clinical Milestones Cambridge, MA – July 14, 2021 – Ribon Therapeutics, a clinical …
Learn MoreJun 28, 2021
Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer
Cambridge, MA – June 28, 2021 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the appointment of …
Learn MoreJun 04, 2021
Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients with Advanced Solid Tumors at 2021 ASCO Annual Meeting
RBN-2397 was well tolerated and demonstrated evidence of target inhibition and preliminary signs of clinical activity One partial response (PR) and nine patients with stable …
Learn MoreMay 20, 2021
Ribon Therapeutics Announces Oral Presentation of RBN-2397 Clinical Data at 2021 ASCO Annual Meeting
Cambridge, MA – May 20, 2021 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that data from …
Learn MoreApr 29, 2021
Ribon Therapeutics Announces Upcoming Presentation on RBN-2397 at the 2021 ASCO Annual Meeting
CAMBRIDGE, Mass. – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced an oral presentation on RBN-2397 at the …
Learn MoreApr 06, 2021
Ribon Therapeutics Announces Upcoming Presentations at the AACR 2021 Virtual Annual Meeting
Cambridge, MA – April 6, 2021 – Ribon Therapeutics, a clinical stage oncology company developing therapeutics targeting stress support pathways, today announced that it will …
Learn MoreFeb 02, 2021
Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries
– Ono to make upfront payment of approximately $16.3 million to Ribon in addition to other potential milestone payments of approximately $132 million Cambridge, …
Learn MoreNov 16, 2020
Ribon Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Cambridge, MA – November 16, 2020 – Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria …
Learn MoreNov 09, 2020
Ribon Therapeutics Announces the Appointment of Emma Reeve to the Company’s Board of Directors
Cambridge, MA – November 9, 2020 – Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the appointment of …
Learn MoreJul 16, 2020
Ribon Therapeutics Announces Appointment of Jodie P. Morrison as Chair of the Company’s Board of Directors
Cambridge, MA – July 16, 2020 – Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Jodie P. …
Learn MoreJun 22, 2020
Ribon Therapeutics Presents Additional Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and Demonstrates Broad Potential of its Platform at the AACR 2020 Virtual Meeting II
-Reinforces PARP7 as a novel therapeutic target and that inhibition of PARP7 induces both antitumor immunity and cancer cell-intrinsic effects– -Platform identifies several cancer-relevant monoPARPs …
Learn MoreMay 26, 2020
Ribon Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Cambridge, MA – May 26, 2020 – Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria …
Learn MoreMay 15, 2020
Ribon Therapeutics to Present New Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and its Discovery Platform at the Upcoming AACR 2020 Virtual Meeting II
-RBN-2397 restores type I IFN signaling in the tumor, causes complete tumor regressions and adaptive immunity in preclinical models- Cambridge, MA – May 15, 2020 …
Learn MoreMay 04, 2020
Ribon Therapeutics to Present at Upcoming Healthcare Conferences
Cambridge, MA – May 4, 2020 — Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria Richon, …
Learn MoreApr 27, 2020
Ribon Therapeutics Presents Preclinical Data from its PARP7 and PARP14 Programs at AACR Virtual Meeting I
— Lead program, PARP7 inhibitor RBN-2397, demonstrates complete tumor regression in preclinical cancer models — — Phase 1 study underway evaluating RBN-2397 in advanced-stage solid …
Learn MoreApr 14, 2020
Ribon Therapeutics to Present New Preclinical Data at the Upcoming AACR Virtual Annual Meetings
Cambridge, MA – April 14, 2020 – Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the presentation …
Learn MoreJan 24, 2020
Ribon Therapeutics to Present at Upcoming Scientific Conferences
Cambridge, MA – Jan. 24, 2020 – Ribon Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress …
Learn MoreJan 06, 2020
Ribon Therapeutics Named as a Top Life Sciences Company to Watch in 2020
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life sciences companies in North America…
Learn MoreDec 18, 2019
Ribon Therapeutics Strengthens Scientific Advisory Board with Appointment of Neal Rosen, M.D., Ph.D.
Cambridge, MA – Dec. 18, 2019 – Ribon Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress …
Learn MoreSep 04, 2019
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor
PARP7 is a Novel Tumor Dependency, Enabling Cancer Cells to Evade the Immune System First Ever Clinical Evaluation of a monoPARP Inhibitor Cambridge, MA – …
Learn MoreAug 06, 2019
Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer
Cambridge, MA – Aug. 6, 2019 – Ribon Therapeutics, a clinical stage biotechnology company, developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress …
Learn MoreJan 04, 2019
Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer
Financing led by the Novartis Venture Fund, with Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Celgene, and existing investors, The Column Group, Deerfield Management, …
Learn More